Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies

Published: Tuesday, September 02, 2014
Last Updated: Tuesday, September 02, 2014
Bookmark and Share
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.

CN Bio Innovations Ltd has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations at three international meetings this Fall, including:

•         The 2014 International Meeting on Hepatitis B in Los Angeles, USA (3-6 September, 2014)
•         The Viral Hepatitis Congress 2014 in Frankfurt, Germany (9-11 October, 2014)
•         The Liver Meeting® 2014*, Boston USA (7-11 November, 2014). CN Bio will also host an Investigator Meeting** on Monday 10th November, which is an invitation-only event for attendees of The Liver Meeting® 2014.

First public presentations

Dr Marcus Dorner, Lead Principle Investigator for the study, commented: “It’s an honour to be invited to present our data at these prestigious meetings, where we’ll show how CN Bio’s Hepatitis B liver disease model accurately recapitulates the full life-cycle of HBV without the need for interventions such as the solvent permeabilization of cells. This makes it a uniquely powerful tool for developing and testing new HBV treatments.”

A breakthrough in HBV research

Dr Emma Sceats, COO at CN Bio said, “The work completed through this collaboration with Dr Dorner and his team represents an important breakthrough. The absence of suitable in vitro and animal models of Hepatitis B limits our ability to effectively analyse the biology and pathology of the disease, making the development of effective drugs very challenging. Hopefully, using new, advanced technologies such as these, novel therapies will reach market more quickly, helping to treat the more than 300 million patients worldwide infected with Hepatitis B.”

*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases
**This event is not an official function/event of the American Association for the Study of Liver Diseases

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos